Trial profile. ∗ indicates the control group patients received supportive care (eg, transfusions, corticosteroids, and supplements [iron, folate, and vitamin B12]); †, patients assigned to the control group could escape to pegcetacoplan therapy if their hemoglobin levels were ≥2 g/dL below their baseline measurement or presented with a qualifying thromboembolic event secondary to PNH; ‡, 1 death occurred in the pegcetacoplan group related to septic shock in the context of bone marrow failure (both events were deemed unrelated to pegcetacoplan); and §, 1 death occurred in the control group related to respiratory failure and septic shock.